Details for Patent: 7,598,279

Which drugs does patent 7,598,279 protect, and when does it expire?

Patent 7,598,279 protects XCOPRI and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 7,598,279

Title:	Neurotherapeutic azole compounds
Abstract:	Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.
Inventor(s):	Yong Moon Choi, Choon-Gil Kim, Han-Ju Yi, Young-Sun Kang, Hyun-Seok Lee
Assignee:	SK Biopharmaceuticals Co Ltd
Application Number:	US11/407,526
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,598,279
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,598,279

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-001	Mar 10, 2020		RX	Yes	Yes				Y
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-002	Mar 10, 2020		RX	Yes	No				Y
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-003	Mar 10, 2020		RX	Yes	No				Y
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-004	Mar 10, 2020		RX	Yes	No				Y

International Family Members for US Patent 7,598,279

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1879873		301106	Netherlands
European Patent Office	1879873		122021000027	Germany
European Patent Office	1879873		CA 2021 00015	Denmark
European Patent Office	1879873		2021C/524	Belgium